Dermapharm Holding SE : TP raised to € 31 on stronger H1 2018 earnings in Parallel Import segment
>Top-line growth mainly acquisition-driven - Dermapharm published its final H1 2018 results today, 12 September. The final results contained no surprises vs the preliminaries published in August. Group revenues were up 19.7% to € 280.3m. EBITDA adjusted for one-off costs of € 3.8m (€ 1.4m for IPO preparations and € 2.4m related to the acquisitions of Strathmann and Trommsdorff) increased 29.9% yoy to € 70.9m (H1 17: € 54.6m), equating to a group adj. EBITDA margin of ...Dermapharm Holding SE. Dermapharm Holding SE is a Germany-based company engaged in manufacturing of patent-free branded pharmaceuticals. The Company operates through two segments: Branded pharmaceuticals and other healthcare products, which includes in-house development, in-house production, and distribution of branded pharmaceuticals and other healthcare products, and Parallel import business, which operates under the axicorp brand. It holds around 950 marketing authorizations for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. The Company offers its products through a number of brands, including Dekristol, Ampho Moronal, Keltican, Tromcardin, among others. It is active primarily in Germany, Switzerland and Austria. Additionally, it operates production facility in Germany. Trommsdorff & GmbH Co KG is a subsidiary of the Company.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.